GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting determination received on August 27, 2026, related to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The hearing is scheduled for October 13, 2026, and the request has stayed any suspension or delisting action, allowing GeoVax's common stock to continue trading on The Nasdaq Capital Market under the symbol "GOVX" at least through the hearing and any extension period granted by the Panel. At the hearing, GeoVax intends to present its plan to regain and maintain compliance with Nasdaq listing standards.
David Dodd, Chairman and CEO, stated, "We remain committed to maintaining GeoVax's Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel. Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution." He added that the company continues to advance GEO-MVA toward a planned pivotal Phase 3 clinical program, pursue opportunities to strengthen manufacturing and global preparedness capabilities, and engage potential strategic, funding, and development partners.
The Nasdaq listing appeal is significant because it provides GeoVax with an opportunity to avoid delisting, which could impact investor confidence and access to capital. However, the company's reaffirmation of its strategic priorities underscores that its core mission remains intact. GeoVax's priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial addressing the need for expanded orthopoxvirus vaccine supply and biodefense preparedness.
In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. The company also maintains a broader MVA-based vaccine platform and intellectual property portfolio addressing high-consequence infectious diseases and global health preparedness.
The implications of this announcement extend beyond the listing issue. By focusing on its strategic priorities, GeoVax aims to build long-term value from its vaccine and immuno-oncology programs while addressing near-term corporate and financing priorities. The growing emphasis on vaccine supply resilience, biodefense preparedness, and expanded global access provides a strong foundation for these efforts. For more information, visit www.geovax.com. The original release can be viewed on www.newmediawire.com.
GeoVax's ability to maintain its Nasdaq listing is crucial for its ongoing development programs, as it ensures continued access to public markets and investor support. The company's focus on high-consequence infectious diseases and solid tumor cancers positions it in areas of significant unmet medical need, and its progress could contribute to global health security. As GeoVax navigates the appeals process, its commitment to advancing its pipeline remains unwavering, with potential impacts on vaccine availability and cancer treatment options.
